Sugi Predict

Sugi Predict / Compounds / SCHEMBL14685779

SCHEMBL14685779

SCHEMBL14685779

CCC[C@H](NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O

nearest known ligand 0.69

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ NOD1 Q9Y239 8/20 0.69
▸ PLA2G2C Q5R387 1/20 0.55
▸ SLC6A5 Q9Y345 2/20 0.55
▸ PLA2G10 O15496 2/20 0.54
▸ GNPAT O15228 1/20 0.53
▸ ALDH1A1 P00352 2/20 0.50
▸ FAAH O00519 2/20 0.49
▸ MEN1 O00255 1/20 0.49
▸ MAPK1 P28482 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ TSHR P16473 1/20 0.48
▸ SLC22A6 Q4U2R8 1/20 0.48
▸ SLC22A8 Q8TCC7 1/20 0.48
▸ GPR84 Q9NQS5 1/20 0.48
▸ PPARG P37231 1/20 0.48
▸ PPARD Q03181 1/20 0.48
▸ PPARA Q07869 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25651310 1.00 NOD1 (0.69) NOD1PLA2G2CSLC6A5PLA2G10GNPAT
SCHEMBL71687 1.00 NOD1 (0.69) NOD1PLA2G2CSLC6A5PLA2G10GNPAT
SCHEMBL8292791 1.00 NOD1 (0.69) NOD1PLA2G2CSLC6A5PLA2G10GNPAT
SCHEMBL29329833 1.00 NOD1 (0.69) NOD1PLA2G2CSLC6A5PLA2G10GNPAT
SCHEMBL14478728 1.00 NOD1 (0.69) NOD1PLA2G2CSLC6A5PLA2G10GNPAT
SCHEMBL18560506 1.00 NOD1 (0.69) NOD1PLA2G2CSLC6A5PLA2G10GNPAT
SCHEMBL23601770 1.00 NOD1 (0.69) NOD1PLA2G2CSLC6A5PLA2G10GNPAT
SCHEMBL18783045 1.00 NOD1 (0.69) NOD1PLA2G2CSLC6A5PLA2G10GNPAT
SCHEMBL14725995 1.00 NOD1 (0.69) NOD1PLA2G2CSLC6A5PLA2G10GNPAT
SCHEMBL18573779 0.97 NOD1 (0.74) NOD1PLA2G2CSLC6A5PLA2G10GNPAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024038067-A1 COMBINATION THERAPY COMPRISING LONG ACTING GLP-1/GLUCAGON AND NPY2 RECEPTOR AGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-02-22 — — WO disclosed
US-11530244-B2 Cyclic polypeptides for PCSK9 inhibition MERCK SHARP & DOHME LLC (US) 2022-12-20 — — US disclosed
WO-2020143625-A1 NOVEL POLYPEPTIDE AND THERAPEUTIC USES THEREOF 鸿绪生物医药科技（北京）有限公司 2020-07-16 — — WO disclosed
US-10570184-B2 GLP-1/glucagon receptor co-agonists for medical use NOVO NORDISK A/S (DK) 2020-02-25 — — US disclosed
EP-2758426-B1 NOVEL GLUCAGON ANALOGUES NOVO NORDISK AS (DK) 2019-08-07 — — EP disclosed
EP-2986313-B1 STABLE, PROTRACTED GLP-1/GLUCAGON RECEPTOR CO-AGONISTS FOR MEDICAL USE NOVO NORDISK AS (DK) 2019-06-12 — — EP disclosed
US-9988430-B2 Stable GLP-1 based GLP-1/glucagon receptor co-agonists NOVO NORDISK A/S (DK) 2018-06-05 — — US disclosed
US-20180021402-A1 MODULATORS OF COMPLEMENT ACTIVITY UCB HOLDINGS, INC. 2018-01-25 — — US disclosed
US-20180016319-A1 Acylated Glucagon Analogues NOVO NORDISK AS (DK) 2018-01-18 — — US disclosed
US-9670261-B2 Functionalized exendin-4 derivatives SANOFI (FR) 2017-06-06 — — US disclosed
US-8815802-B2 GLP-1 analogues and derivatives NOVO NORDISK A/S (DK) 2014-08-26 — — US disclosed
US-8815802-B2 GLP-1 analogues and derivatives NOVO NORDISK A/S (DK) 2014-08-26 — — US disclosed
US-20140206609-A1 Functionalized Exendin-4 Derivatives SANOFI (FR) 2014-07-24 — — US disclosed
US-20140206609-A1 Functionalized Exendin-4 Derivatives SANOFI (FR) 2014-07-24 — — US disclosed
EP-2708554-A1 Insulin analogues with an acyl and alkylene glycol moiety NOVO NORDISK A/S (DK) 2014-03-19 — — EP disclosed
US-20130143798-A1 NOVEL GLUCAGON ANALOGUES NOVO NORDISK A/S (DK) 2013-06-06 — — US disclosed
US-20130143798-A1 NOVEL GLUCAGON ANALOGUES NOVO NORDISK A/S (DK) 2013-06-06 — — US disclosed
US-20130053311-A1 GLP-1 ANALOGUES AND DERIVATIVES NOVO NORDISK A/S (DK) 2013-02-28 — — US disclosed
US-20130053311-A1 GLP-1 ANALOGUES AND DERIVATIVES NOVO NORDISK A/S (DK) 2013-02-28 — — US disclosed
US-20130035285-A1 NOVEL GLUCAGON ANALOGUES NOVO NORDISK A/S (DK) 2013-02-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130143798-A1 NOVEL GLUCAGON ANALOGUES GLP1R, GCG, IAPP NOD1 1083/4885PLA2G2C 478/4885SLC6A5 1154/4885
US-20180021402-A1 MODULATORS OF COMPLEMENT ACTIVITY C3AR1, C1QBP, C5AR1 NOD1 1517/4885PLA2G2C 94/4885SLC6A5 4587/4885
US-20180016319-A1 Acylated Glucagon Analogues GLP1R, GCG, IAPP NOD1 2294/4885PLA2G2C 378/4885SLC6A5 1550/4885
US-10570184-B2 GLP-1/glucagon receptor co-agonists for medical use GLP1R, GCGR, GIPR NOD1 762/4885PLA2G2C 2876/4885SLC6A5 1567/4885
US-11530244-B2 Cyclic polypeptides for PCSK9 inhibition PCSK9, LDLR, PCSK7 NOD1 2513/4885PLA2G2C 548/4885SLC6A5 4813/4885
US-20130035285-A1 NOVEL GLUCAGON ANALOGUES GLP1R, GIPR, IAPP NOD1 1856/4885PLA2G2C 1078/4885SLC6A5 2017/4885
US-20140206609-A1 Functionalized Exendin-4 Derivatives GLP1R, NPY4R, MC4R NOD1 1330/4885PLA2G2C 2933/4885SLC6A5 1085/4885
US-20130053311-A1 GLP-1 ANALOGUES AND DERIVATIVES GLP1R, IAPP, SLC5A1 NOD1 221/4885PLA2G2C 1816/4885SLC6A5 414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback